# M1231 in Participants With Solid Tumors

> **NCT04695847** · PHASE1 · COMPLETED · sponsor: **EMD Serono Research & Development Institute, Inc.** · enrollment: 23 (actual)

## Conditions studied

- Metastatic Solid Tumors
- Esophageal Cancer
- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** M1231
- **DRUG:** M1231

## Key facts

- **NCT ID:** NCT04695847
- **Lead sponsor:** EMD Serono Research & Development Institute, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-13
- **Primary completion:** 2023-06-23
- **Final completion:** 2023-06-23
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2023-07-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04695847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04695847, "M1231 in Participants With Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04695847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*